Homocysteine, vitamins, and coronary artery disease: Comprehensive review of the literature

Canadian Family Physician

Volumn 46, Issue NOV., 2000, Pages 2236-2245

  Taylor, Brian V ^b   Oudit, Gavin Y ^b   Evans, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART DISEASE; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PROPHYLAXIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

CLINICAL TRIALS; CORONARY DISEASE; DIET; FOLIC ACID; HOMOCYSTEINE; HUMANS; PYRIDOXINE; RISK FACTORS; VITAMIN B 12;

EID: 0033636492     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: a possible role for methionine metabolism. J Clin Invest 1976;57:1079-82.
2. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Glassman E, Gaull GE, et al. Methionine intolerance. J Am Coll Cardiol 1985;6:725-30.
3. Kang S, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine. J Clin Invest 1986;77:1482-6.
4. Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-33.
5. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice. Coron Artery Dis 1990;1:215-20.
6. Genest JJ, McNamara JR, Salem DN, Wilson PWF, Scaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990;16:1114-9.
7. Ubbink JB, Vermaak WJH, Bennet JM, Becker PJ, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary artery disease. Klin Wochenschr 1991;69:527-34.
8. Clarke R, Daly L, Robinson K, Naughten E, Cahalam S, Fowler B, et al. Hyperhomocysteinemia: an independent risk for vascular disease. N Engl J Med 1991;324:1149-55.
9. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease Arterioscler Thromb 1993;13:1253-60.
10. 12 concentrations and risk for early onset coronary artery disease. Am J Clin Nutr 1994;59:940-8.
11. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams R, et al. Plasma homocysteine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-61.
12. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
13. Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, et al. Plasma homocysteine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary artery disease. Atherosclerosis 1996;126:27-34.
14. Von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, et al. Effects of age, lipoproteins, and hemostatic parameters on the role of hyperhomocysteinemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:4604.
15. Hopkins PN, Wu LL, Wu J, Hunt SC, James BC, Vincent GM. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995;15:1314-20.
16. 6, pyridoxal phosphate and folate. Am J Cardiol 1995;75:1107-11.
17. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-30.
18. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.
19. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
20. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forder OH, Nordrehaug JE. Serum total homocysteine and coronary artery disease. Int J Epidemiol 1995;24:704-9.
21. Wald NJ, Watt HC, Law MR, Weir DG, McPartin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
22. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
24. Stehouwer CD, Weijenberg MP, van den Berg, Jacobs C, Feskens EJ, Kromhout D. Serum homocysteine and risk of coronary artery disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-901.
25. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in SLE. Lancet 1996;348:1120-4.
26. Bots ML. Launer IJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1998;159:38-44.
27. 6, and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:13643.
28. Alfthan A, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994;106:9-19.
29. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947-53.
30. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998;98:204-11.
31. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent CABG. Am J Cardiol 1997;79:799-801.
32. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscter Thromb Vasc Biol 1997;17:989-95.
33. 12 and folate. Am J Epidemiol 1996;143:845-59.
34. 6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97:437-43.
35. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest 1992;22:214-21.
36. Selhub J, Jacques PF, Wislon PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
37. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hutlberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 1994;236:633-41.
38. Kang S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-62.
39. Lewis CA, Pancharuniti N, Sauberlich HE. Plasma folate adequacy as determined by homocysteine level. Ann N Y Acad Sci 1992;669:360-2.
40. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764-79.
41. Lindenbaum J, Rosenberg IH, Wislon PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
42. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal staus. Eur J Clin Invest 1992;22:79-87.
43. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 1994;40:873-81.
44. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-6.
45. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Serum total homocysteine and coronary heart disease in middle-aged British men [abstract]. Heart 1996;75:53.
46. Witteman BML, Hoes AW, Kuodstaalm PJ, Grobbee DE. Homocysteine and risk of cardiovascular disease in the elderly: the Rotterdam Study [abstract]. Can J Cardiol 1997;13(Suppl B): 150B.
47. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL, Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 1988;48:215-21.
48. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgietes HC. Vitamin requirements for the treatment of hyperhomcysteinemia in humns. J Nutr 1994;24:1927-33.
49. Brattstrom LE, Israelsson B, Norrving B, Bergquist D, Thorne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral arterial occlusive disease. Atherosclerosis 1990;81:51-60.
50. Brattstrom LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985;34:1073-7.
51. Franken DG, Boers GHJ,Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465-70.
52. 6 and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
53. Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983;309:448-53.
54. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993;71:993-8.
55. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, et al. Reduction of plasma folate homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-15.
56. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine theory of vascular disease. J Cardiovasc Risk 1998;5:249-55.
57. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9.
58. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox stsus of cysteine, cysteinglycine, homocysteine and glutathione in human plasma. Anal Biockem 1992;200:218-29.
59. Malinow MR, Axthelm MK, Merdith MJ, MacDonald NA, Upson BM. Synthesis and transsulfuration of homocysteine in blood. J Lab Clin Med 1994;123:421-9.
60. Rasmussen K, Moller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996;42:630-6.
61. 12? Can Fam Physician 1997;43:917-22.
62. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
63. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocysteine and risk of ischemic stroke. Stroke 1994;25:1924-30.
64. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991;13:128-36.
65. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
66. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991;51:828-35.
67. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 1989;114:473-501.
68. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr, editor. Atherosclerotic cardiovascular disease, hemostasis and endothelial function. New York, NY: Marcel Dekker; 1992. p. 177-84.
69. Taylor BV, Oudit GY, Kalman PG, Liu P. Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system. Can J Cardiol 1998;14(9):1129-39.
70. Mudd SH, Levy HL, Skovby F. Disorders of transsulufration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 1. New York, NY: McGraw-Hill; 1995. p. 1279-327.
71. Mudd SH, Sovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homcystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985;37(2):1-31.
72. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-6.
73. Van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997;95:21-3.
74. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary artery disease: evidence for a common gene mutation. Circulation 1996;94:2154-8.
75. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WO, Taylor LM Jr, et al. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996;94:3074-8.
76. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
77. Stamler JS, Osborne JA, Jaraki O, Rabboni LE, Mullins M, Singel D, et al. Adverse vascular effects of homocyteine are modulated by endothelium-derived relaxing fsctor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
78. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997;95:1119-21.
79. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-70.
80. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JA, Schooderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
81. 6 from diet and supplements in relation to risk of coronary artery disease among women. JAMA 1998;279:359-64.
82. Rinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. Am J Pathol 1949;25:481-91.
83. 6: relationship to atherosclerosis. J Nutr 1983;113:2122-33.
84. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 1995;26:1166-70.
85. DeBree A, van Dusseldop M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP. Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 1997;51:643-60.
86. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylene tetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997;28:1739-43.
87. Brattstrom L, Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Homocysteine Lowering Trialist's Collaboration. BMJ 188;316:894-8.